Pharmaceutical US drug developer GenVec said yesterday that it is collaborating with Swiss drug major Novartis to discover and develop novel treatments for hearing loss and balance disorders, which could see it earning up to $213.6 if certain objectives are achieved, including upfront and milestone payments, in addition to royalties on future sales. The news saw GenVec's shares leap 21% to $2.11 in market trading on January 19. 20 January 2010